Abstract:Radioimmunotherapy (RIT) is a novel and promising cancer treatment method, with ongoing research focusing on RIT antibody selection, radionuclides, treatment options, and benefited patient groups. As we dive into the mechanisms of tumor biology, a deeper exploration of how RIT affects tumor tissue is needed to provide new ways to improve clinical treatment outcome and patient prognosis. We labeled the anti-PD-L1 monoclonal antibody atezolizumab with iodine-131 (131I), separated and purified the labeled mAb with Sephadex G-25 medium gel filtration resin, and tested product stability. We detected the in vivo activity of 131I-PD-L1 mAb by analyzing its in vivo biodistribution and performing SPECT imaging and then set different treatment groups to study the effect of 131I-atezolizumab on the survival of tumor-bearing mice. Western blot, real-time quantitative PCR, and immunohistochemistry were used to detect the expression level of Caspase8 and Nlrp3 in tumor. TUNEL fluorescence staining was used to detect the apoptosis in the tumor. The radiopharmaceutical molecular probe 131I-atezolizumab showed high stability and in vivo biological activity. The treatment regimen adopted had a positive effect on the survival of tumor-bearing mice. 131I internal irradiation upregulated Caspase8 in tumor and ultimately inhibited solid tumor growth by activating apoptosis pathways. We also found a significant increase in the expression of NLRP3, which plays an important role in the pyroptosis pathway, in tumor. In summary, our data demonstrated that radiopharmaceuticals combined with immunotherapy affected tumor tissue by modulating relevant biological pathways, thereby achieving better antitumor effects compared with single therapy and providing new insights for promoting better patient prognosis and combination treatment strategies.

Optimizing Radioimmunoconjugate Delivery in the Treatment of Solid Tumor

Radiosensitizer-based Injectable Hydrogel for Enhanced Radio-Chemotherapy of TNBC

Radioimmunotheragnosis in Cancer Research

Radiotheranostic Agents in Hematological Malignancies

Intranuclear Irradiation Inhibits Solid Tumor Growth by Upregulating Caspase8 and Activating Apoptosis

Targeted therapy of cancer with radiolabeled antibodies

Pretargeted radioimmunotherapy with the novel anti-oxMIF/HSG bispecific antibody ON105 results in significant tumor regression in murine models of cancer

Radioimmunotherapy in colorectal cancer treatment: present and future

Aptamer-based Radioimmunotherapy: the Feasibility and Prospect in Cancer Therapy

Radiopharmaceuticals Heat Anti-Tumor Immunity

Treating Deep-Seated Tumors with Radio-Dynamic Therapy: Progress and Perspectives

Novel Approaches to Improve the Efficacy of Immuno-Radiotherapy

Angiogenesis and Immune Checkpoint Dual Blockade in Combination with Radiotherapy for Treatment of Solid Cancers: Opportunities and Challenges

Epigenetic modification in radiotherapy and immunotherapy for cancers

Radiotherapy and Immunotherapy: a Beneficial Liaison?

Immunological effects of radiopharmaceutical therapy

Treating Deep-Seated Tumors with Radiodynamic Therapy: Progress and Perspectives

Delivery Techniques for Enhancing CAR T Cell Therapy Against Solid Tumors

Enhanced Tumor Inhibiting Effect of 131I-Bdi-1-based Radioimmunotherapy and Cytosine Deaminase Gene Therapy Modulated by a Radio-Sensitive Promoter in Nude Mice Bearing Bladder Cancer

Radiotherapy-Mediated Immunomodulation and Anti-Tumor Abscopal Effect Combining Immune Checkpoint Blockade

Radioimmunotherapy in Treatment of Unresectable Hepatoma—a Report of 43 Cases